Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Explore this paper's citation graph
Summary
Interestingly, the mutations identified resulted in premature chain termination or direct abrogation of histone methyltransferase activity, suggesting that EZH2 acts as a tumor suppressor for myeloid malignancies.
- Type
- article
- Published
- 2010-08-01
- Cited by
- 1,202
- References
- 39
- OpenAlex
- https://openalex.org/W1963736125
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:743612
Keywords
Biology, PRC2, EZH2, Histone methyltransferase, Histone H3
References
- An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.
- Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis.
- A bivalent chromatin structure marks key developmental genes in embryonic stem cells.
- Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation
- Accurate Detection of Uniparental Disomy and Microdeletions by SNP Array Analysis in Myelodysplastic Syndromes with Normal Cytogenetics
- Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays.
- Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
- Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
- Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein.
- Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms
- Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
- Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
- JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
- PcG Proteins, DNA Methylation, and Gene Repression by Chromatin Looping
- Mitotic recombination in haematological malignancy.
- Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites.
- Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation
- Mutation in TET2 in myeloid cancers.
- Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Cited by
- JAK2V617F-positive Myeloproliferative Neoplasms : KI mouse models, Interferon-α therapy and clonal architecture
- Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
- IDH1 and IDH2 mutations in myeloid neoplasms – Novel paradigms and clinical implications
- Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma.
- Transcriptional regulation of cellular senescence
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- Myelodysplastic Syndromes
- Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms
- Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase
- Focus on the epigenome in the myeloproliferative neoplasms.
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
- Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia
- Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
- Single-Molecule Decoding of Combinatorially-Modified Nucleosomes
- Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
- The Yin and Yang of cancer genes.
- A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy
- Leukemogenic Mechanisms of MLL Fusion Proteins.
- Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.
- Genome-based technologies provide novel insights into the pathogenesis and the clinical response of lymphoid malignancies
Related papers
- Inhibition of Polycomb Repressive Complex 2 activity reduces trimethylation of H3K27 and affects development in Arabidopsis seedlings
- Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma
- Non-canonical functions of the Polycomb group protein EZH2 in breast cancer.
- Weaver Syndrome‐Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro
- The Interaction between Histone Lysine Methyltransferase GLP and EZH2
- EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer
- Roles of EZH2 Histone Methyltransferase in Tumorigenesis
- The Regulation of EZH2 Activity by PHF1